Erenumab (Aimovig)
The new migraine injection

If you suffer from migraine and you feel as if it’s impacting your relationships, work and personal life, you’re not alone. Migraine is the third most common disease worldwide, affecting around 1 in 7 people*. If you feel like you’ve used all treatment options and nothing has worked, you’re not alone either. Many migraine patients feel like painkillers and other migraine medicines do not work for them, or they can’t take them long-term. But now there’s a new hope.

*According to The Migraine Trust

Please note this page contains information about overseas approved prescription medicines. This includes transparent information such as clinical trials published, how the product works and pricing. If you scroll down, you declare yourself as requesting this information.

The newly approved migraine injection

Erenumab (Aimovig) is the first approved migraine injection that could offer new hope for people who suffer from migraine. According to the Food and Drug Administration (FDA), erenumab (Aimovig) is, globally, the first and only approved CGRP receptor blocker and the first in a new class of preventative migraine medicines1.

What is erenumab (Aimovig)?

Erenumab (Aimovig) is an injection for migraine, which is taken once per month. Clinical studies published by the FDA show that it may offer relief for people with chronic and episodic migraine, by blocking specific molecules that are thought to play a role in migraine.2 Aimovig was also approved by the Therapeutic Goods Administration (TGA) in 2018, and shortly after by the Swissmedic, European EMA and Health Canada3,4,5,6.

Read here for more information about treatment expenses and availability.

How effective is erenumab (Aimovig) according to the studies?

After 3 months, people taking erenumab (Aimovig) experienced 6-7 fewer monthly migraine days
 on average1
After 6 months, people taking erenumab (Aimovig) experienced 3-4 fewer monthly migraine
 days on average1
Aimovig 70 mg
Aimovig 140 mg
*. Aimovig™ (erenumab-aooe) prescribing information, Amgen. ** Goadsby PJ, Reuter U, Hallström Y, et al. A controlled trial of erenumab for episodic migraine. N Engl J Med. 2017;377(22):2123-2132. *** Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial Tepper, Stewart et al. The Lancet Neurology ,
 Volume 16 , Issue 6 , 425 - 434

How to use the new migraine injection (erenumab)*

Erenumab (Aimovig) comes in a simple SureClick autoinjector2.
It is taken by pressing the autoinjector against your skin and pressing a button2. (This injection may be comparable with using an insulin-autoinjector).
Aimovig is available in two dosages, 70 mg and 140 mg, both of which are available in a single injection2.
*This information is not intended to be a guide for taking erenumab (Aimovig). Please consult the full prescribing information and administration instructions before using erenumab (Aimovig).

How do these new blockers like erenumab (Aimovig) work?

Research shows that during migraines, there is an increase in calcitonin gene-related peptide (CGRP) which is thought to play a role in what causes migraines and how they are felt7.
The active ingredient in erenumab (Aimovig) blocks the receptor of CGRP7.
By blocking CGRP and its receptor, it’s thought that treatments like erenumab (Aimovig) reduce the frequency of migraine7.

How can I get erenumab (Aimovig)?

It may be the case that erenumab is not yet approved or available in your country, which may mean you will experience delays in accessing this medicine. We’re here to help.

With a prescription from your treating doctor TheSocialMedwork can support you to obtain erenumab (Aimovig) from outside your country. Our team of pharmacists and regulatory experts delivers elsewhere approved medicines around the world every day. They are ready to assist with sourcing and delivery, and will guide you through every step of the process.

Enquire Now

Need support?

Migraine is a challenging and under-recognised disorder. If you’d like to ask questions about erenumab (Aimovig), how to get it, or about any other migraine treatments, our team of qualified pharmacists and experts are ready to offer support and assist with queries. Our team speaks 17 different languages and is ready to help.

Who is TheSocialMedwork?

TheSocialMedwork makes the latest approved medicines available to patients, hospitals and doctors around the world, in a legal and compliant way. We source the best possible prices for innovative medicines and ensure safe, efficient and legally compliant delivery. We have successful deliveries in over 60 countries worldwide, with 100% quality service reviews by doctors and patients.


  1. FDA approves novel preventive treatment for migraine. 17/05/2018.
  2. Aimovig. Cited 18/07/2018.
  3. TGA Public Summary: Aimovig [PDF], July 2,2018. 
  4. Novartis-Migränemedikament Aimovig wird in der Schweiz zugelassenLuzerner Zeitung, July 16, 2018.
  5. Novartis Press Release: Novartis marks a new era for migraine patients with the EU approval of Aimovig, a first-of-its-kind treatment specifically designed for migraine prevention,
    July 30, 2018.
  6. Novartis Press Release: AimovigTM (erenumab), a novel treatment developed specifically for migraine prevention receives Health Canada approval,
    August 1, 2018.
  7. CGRP as the target of new migraine therapies. Edvinsson L. et al. Nature Reviews Neurology. 24/04/2018; volume 14: 338–350.